Kalaris Therapeutics, Inc. Asset Resilience Ratio
Kalaris Therapeutics, Inc. asset resilience ratio. Kalaris Therapeutics, Inc. (KLRS) has an Asset Resilience Ratio of 57.18% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See KLRS days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Kalaris Therapeutics, Inc. (2019–2025)
Asset resilience ratio of Kalaris Therapeutics, Inc. from 2019 to 2025. This chart shows how Kalaris Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. Read debt load of Kalaris Therapeutics, Inc. for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Kalaris Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see KLRS current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $62.79 Million | 57.18% |
| Total Liquid Assets | $62.79 Million | 57.18% |
Asset Resilience Insights
- Very High Liquidity: Kalaris Therapeutics, Inc. maintains exceptional liquid asset reserves at 57.18% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Kalaris Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Kalaris Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Kalaris Therapeutics, Inc. Asset Resilience Ratio by Year (2019–2025)
Kalaris Therapeutics, Inc. asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Kalaris Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 16.37% | $19.93 Million | $121.74 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $118.55 Million | -- |
| 2021-12-31 | 16.21% | $46.46 Million | $286.59 Million | -46.80pp |
| 2020-12-31 | 63.01% | $233.66 Million | $370.82 Million | +16.40pp |
| 2019-12-31 | 46.62% | $64.99 Million | $139.42 Million | -- |
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudativ… Read more